Syncom Formulations (India) Ltd
BSE:524470
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
S
|
Syncom Formulations (India) Ltd
NSE:SYNCOMF
|
12.6B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
997.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
281.1B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
303.5B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
230.9B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.1B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.7B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD |
Loading...
|
Market Distribution
| Min | -305 007.7% |
| 30th Percentile | 2.1% |
| Median | 5.8% |
| 70th Percentile | 11.6% |
| Max | 1 221 633.3% |
Other Profitability Ratios
Syncom Formulations (India) Ltd
Glance View
Syncom Formulation India Ltd. is a pharmaceutical company, which engages in the development, manufacture, and marketing of healthcare products. The company is headquartered in Indore, Madhya Pradesh. The firm manufactures and markets more than 300 pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquid orals, liquid vials and ampoule injections and dry vial injections, dry syrups, ointments and inhalers. Its segments include Pharmaceuticals Drugs & Formulations, Trading of Commodities and Renting of property. Its product categories include tablets, capsules, ointments, injections, liquid-oral and packaging variants. The company offers various products, including generics, alpha adrenoceptor agonist, analgesic, antipyretic, anti-inflammatory, anti-ulcer agents, antibiotic, antidepressant, antiviral, cephelo sporins, cortico steroid, estrogen, cough suppressant and sedative anticonvulsant, among others. The firm operates in more than 15 countries across the world.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Syncom Formulations (India) Ltd is 11.6%, which is above its 3-year median of 10.3%.
Over the last 2 years, Syncom Formulations (India) Ltd’s Net Margin has increased from 9.7% to 11.6%. During this period, it reached a low of 9.6% on Mar 31, 2024 and a high of 11.6% on Jul 30, 2025.
